

Format for ANSWERING REVIEWERS



June 21, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 11420_Review.doc).

Title: Chronic Kidney Disease and Erectile Dysfunction

Author: Etsu Suzuki, Hiroaki Nishimatsu, Shigeyoshi Oba, Masao Takahashi, Yukio Homma

Name of Journal: *World Journal of Nephrology*

ESPS Manuscript NO: 11420

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

Responses to Reviewer#1

- 1) Sildenafil is commonly and safely used without dose reduction for the treatment of ED in dialysis patients. We have accordingly described it in the revised manuscript (page 16, line 6). The usage of vardenafil and tadalafil for the treatment of ED in dialysis patients is contraindicated in Japan. Because we do not clearly know whether the usage of these drugs in dialysis patients is permitted in other countries, we decided not to describe this information in the revised manuscript.
- 2) To the best of our knowledge, electrical nerve stimulation is not commonly used for the treatment of ED in hemodialysis patients, although it is sometimes used during total prostatectomy to preserve the cavernous nerve. We have not described this method in the revised version because we believe it is beyond the scope of this manuscript.
- 3) The efficacy of bromocriptine for the treatment of ED in dialysis patients has been previously reported (Bommer J et al. Lancet 1979;2:496, Muir JW et al. Clin Nephrol 1983;20:308). However, those reports were published before PDE5Is were discovered and used to treat ED in dialysis patients. Furthermore, the usefulness of bromocriptine has been limited by a high frequency of side effects such as hypotension. Because PDE5Is have been safely used for the treatment of ED in dialysis patients and bromocriptine is seldom used (at least in Japan), we decided not to include this discussion in the revised manuscript.

Responses to Reviewer#2

Please refer to our responses to Reviewer #1. Unfortunately, we are unable to understand what is specifically meant by "any other new treatment for ED in CKD." We would appreciate if you could elaborate further so that we can address your question adequately.

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Etsu Suzuki', written in a cursive style.

Etsu Suzuki, M.D., Ph.D.
Institute of Medical Science
St. Marianna University School of Medicine
2-16-1 Sugao
Miyamae-ku
Kawasaki 216-8512
Japan
e-mail: esuzuki-ty@umin.ac.jp
Fax: 044-977-8361